Boehringer Ingelheim and Click Therapeutics have announced a significant strategic agreement centered on the commercialization of CT-155. This investigational prescription digital therapeutic targets the negative symptoms of schizophrenia in adults. As part of the deal, Boehringer has made a $50 million Series D investment in Click, transferring full commercial rights for the co-developed product.
A Strategic Shift in Digital Therapeutics
The new arrangement places Click Therapeutics in charge of all commercial and marketing authorization responsibilities for CT-155. This transfer is bolstered by Boehringer's substantial financial backing, which includes the strategic investment and additional dedicated funding for commercialization. The move leverages Click's specialized expertise in digital therapeutics to guide the product through its final stages to market, pending regulatory clearance.
David Benshoof Klein, CEO of Click Therapeutics, described the selection as a powerful validation of the company's vision and capabilities. He expressed eagerness to lead the effort in bringing the FDA-designated Breakthrough Device to patients. This transition underscores a growing confidence in specialized digital health companies to successfully commercialize novel therapeutic software.
Promising Clinical Trial Results
The commercialization strategy is anchored by strong results from the Phase III CONVOKE study. This pivotal trial was the first to demonstrate a statistically significant reduction in the experiential negative symptoms of schizophrenia. The study's success provides a robust clinical foundation for CT-155 as an adjunct to standard antipsychotic therapy.
Data presented at the European College of Neuropsychopharmacology Congress revealed that the study met its primary endpoint. Patients using CT-155 showed a 6.8-point improvement on the CAINS-MAP scale at 16 weeks, a 62% relative improvement over the digital control arm. This outcome reflects a meaningful clinical impact on a challenging aspect of the condition.
Safety and Future Development
In addition to its effectiveness, CT-155 demonstrated a favorable safety profile throughout the trial. The digital therapeutic was well-tolerated, with an adverse event rate of 8.3% compared to 13.4% in the control group. Importantly, there were no serious adverse events related to CT-155 and no trial discontinuations attributed to the treatment.
While Click prepares for commercialization, further data is being collected through the ongoing ENSPIRUS study. Boehringer Ingelheim will continue to lead this study to completion, generating additional clinical and engagement data in real-world settings. This continued collaboration ensures a comprehensive understanding of the therapeutic's performance before its potential launch.
A New Chapter for Schizophrenia Treatment
Jan Stefan Scheld of Boehringer Ingelheim highlighted the collaboration's role in advancing a meaningful innovation for people with schizophrenia. He stated that the agreement enables Click to leverage its expertise to maximize the impact of CT-155. This partnership exemplifies a strategic approach to fostering science and creating new treatments for patients with high unmet needs.
This strategic realignment, backed by a $50 million investment and compelling clinical evidence, marks a pivotal moment for CT-155 and the digital therapeutics field. By entrusting commercialization to Click Therapeutics, Boehringer Ingelheim is championing a specialized approach to bringing this novel schizophrenia treatment to market. The collaboration paves the way for a new therapeutic option that could significantly improve the lives of patients, pending final FDA clearance.